Navigation Links
Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information
Date:3/29/2011

NEW HAVEN, Conn., March 29, 2011 /PRNewswire/ -- USChina Channel LLC announced today:

On March 11, 2011, Bill Guo, Chairman of Commonwealth Biotechnologies Inc. ("CBI") filed Form 8-k of SEC, to announce the detail of 2011 Annual Shareholder Vote & Meeting. The vote process is going very well.

We already have shareholders representing over 3 million shares of common stock made the vote. Followings are the interim vote results for the four proposals:PROPOSAL 001 ELECTION OF DIRECTOR: BILL GUOFOR

AGAINST

ABSTAIN

BROKER NONE-VOTESBENEFICIAL

366,658

21,848

0REGISTERED

2,615,693

0

0TOTAL SHARE VOTED

2,982,351

21,848

0% OF VOTED

99.27%

0.72%

0.00%% OF OUTSTANDING

24.66%

0.18%

0.00%PROPOSAL 002 REVISE OF ARTICLE OF CBI & ACCEPT MIN. 1 MEMBER OF DIRECTORS OF BOARDFOR

AGAINST

ABSTAIN

BROKER NONE-VOTESBENEFICIAL

365,658

22,848

0REGISTERED

2,615,693

0

0TOTAL SHARE VOTED

2,981,351

22,848

0% OF VOTED

99.23%

0.76%

0.00%% OF OUTSTANDING

24.65%

0.18%

0.00%PROPOSAL 003 REVISE OF BYLAWS OF CBI & ACCEPT MIN. 1 MEMBER OF DIRECTORS OF BOARDFOR

AGAINST

ABSTAIN

BROKER NONE-VOTESBENEFICIAL

365,658

22,848

0REGISTERED

2,615,693

0

0TOTAL SHARE VOTED

2,981,351

22,848

0% OF VOTED

99.23%

0.76%

0.00%% OF OUTSTANDING

24.65%

0.18%

0.00%PROPOSAL 004 SALARY & COMPES. OF NEW DIRECTOR WILL BE $1 PER YEARFOR

AGAINST

ABSTAIN

BROKER NONE-VOTESBENEFICIAL

388,206

300

0REGISTERED

2,615,693

0

0TOTAL SHARE VOTED

3,003,899

300

0% OF VOTED

99.99%

0.00%

0.00%% OF OUTSTANDING

24.83%

0.00%

0.00%There are 99.99% of the voted shares approved the proposal that the salary and compensation of new director(s) would be $1 per year. To cut the overhead expenses sharply became the whelming demands of the voted shareholders.

These shareholders, who haven't voted, could go to www.proxyvote.com making a vote now. Whether you agree or disagree, your voice is important for CBI which is in a critical status for fighting surviving.

We welcome all shareholders to attend the CBI 2011 Annual Shareholders Meeting, which will be held at 10:00 a.m. EDT, on April 4, 2011. The meeting will be held electronically via telecom.  Here is the url address that has been assigned for your virtual annual meeting: 

http://www.virtualshareholdermeeting.com/CBTE

Shareholders will be able to log onto the above site approximately 15 minutes prior to the meeting to listen to the proceedings, view the annual meeting materials, vote their shares and ask a question if they choose to do so. 

Since we suspended SEC reporting status, shareholders could go to the url address www.otcmarkets.com from CBI trading symbol or name to find the limited communication between company and public.

If you have any question, please contact:

Bill Guo  Address: Venturepharm Towers

USA: C/o Agent: Andrew ChienNo. 3 Jinzhuang, Sijiqing, Haidian District

665 Ellsworth AvenueBeijing, China PC 100089

 New Haven, CT 06511Tel: 86-10-88500088

Tel: 203-8440809Fax: 86-10-88500080

Fax: 8665716313E-mail: la@venturepharm.com

E-mail: uschien@uschinachannel.netWe hired InvestorCom, Inc to do proxy solicitation, and any one could contact them by:

John Glenn Grau, President.  InvestorCom, Inc., www.investor-com.com65 Locust Avenue, Third Floor,  New Canaan, CT   06840P (203) 972-9300 ext. 11   F (203) 966-6478
M (646) 242-041045 Park Avenue, Suite 3900, New York, NY
7P (212) 668-0800
'/>"/>

SOURCE Commonwealth Biotechnologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
2. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
3. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
4. Epeius Biotechnologies REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
5. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
6. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
7. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
10. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
11. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):